Page 1

Jaguar Health Exhibit 99.1 Jaguar Health Reports Second Quarter 2026 Financials Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure ( IF ) diseases ; as announced , presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF , which demonstrate reduction of parenteral support normalized to body weight of up to 48 % in patient with the ultrarare microvillus inclusion disease ( MVID ) ; company expects clinical package for NDA for MVID to be ready by end of 2026 , allowing submission of NDA in Q2 2027 REMINDER : Jaguar to host investor webcast Wednesday , August 19 at 4:30 p.m. Eastern regarding Q2 2026 financials and company updates ( click here to register ) SAN FRANCISCO , CA / August 19 , 2026 / Jaguar Health , Inc. ( NASDAQ : JAGX ) ( “ Jaguar ” or the " Company " ) today reported its consolidated second - quarter 2026 financial results . 2026 SECOND QUARTER COMPANY FINANCIAL RESULTS : License and Grant Revenue : Effective January 12 , 2026 , Jaguar entered a U.S. commercial licensing agreement with Woodward Specialty , LLC ( " Woodward " ) , an affiliate of privately held Future Pak , LLC ( “ Future Pak " ) . Under the terms of the agreement , Future Pak is now the exclusive U.S. marketer for the Company's Mytesi® and Canalevia® - CA1 products . License revenues for the initial $ 16 million upfront payment , in addition to the $ 3 million payment for early termination of the Buy - Back Option under this agreement , were recognized by the Company in the first quarter of 2026. As announced in August 2026 , Jaguar has satisfied the closing conditions required to receive payment of the non - dilutive $ 2 million holdback amount of the upfront fee from Future Pak . Napo remains the manufacturer of crofelemer and Mytesi and supplies product to Future Pak at cost - plus terms . Additionally , the Company recognized license fees of $ 43,000 in the second quarter of 2026 from a securities purchase agreement with a European partner , which was supported by a binding term sheet . Approximately $ 43,000 of license fees were consistently recognized in each of the quarters of 2025 under this agreement . As of June 30 , 2026 , the total deferred revenue associated with this contract amounts to $ 468,000 . Federal grant revenue recognized in the second quarter of 2026 for the clinical study related to the treatment of chemotherapy - induced diarrhea ( " CID " ) in dogs was $ 25,520 and none in 2025 . Prescription Product Revenue , Net : The total net revenue for the Company's prescription products ( Mytesi , Gelclair , and Canalevia - CA1 ) was approximately $ 1.2 million in the second quarter of 2026 , which was compromised primally of sales of Mytesi at cost - plus to Future Pak . In January 2026 , Jaguar entered into a royalty - free license agreement with Future Pak . Under this agreement , all revenues generated in the United States from Mytesi and Canalevia - CA1 , effective from January 12 , 2026 , are directed to Future Pak . Future Pak is privately held and does not report Mytesi sales . Compared to the second quarter of 2025 , the number of Mytesi bottles the Company sold in the second quarter of 2026 increased significantly and commercial costs were substantially decreased . The decision to enter a commercial license agreement with Future Pak aligns with Jaguar's strategic focus on advancing the development of its powder - for - oral - solution formulation of crofelemer for rare - disease indications related to intestinal failure in humans . The total net revenue for the Company's prescription products in the second quarter of 2026 represents a decrease of approximately 2 % compared to the first quarter of 2026 , when total net revenue for prescription products was approximately $ 1.2 million . Additionally , prescription products net revenue decreased by 60 % compared to the second quarter of 2025 , when total revenues amounted to approximately $ 2.9 million .